Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024

がん・腫瘍プロファイリングの世界市場予測(~2024年):イムノアッセイ、NGS、PCR、in situハイブリダイゼーション

◆タイトル:Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024
◆商品コード:MD 4803
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年6月28日
◆ページ数:224
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、がん・腫瘍プロファイリングの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、技術別(イムノアッセイ、NGS、PCR、in situハイブリダイゼーション)分析、がん種類別(乳房、肺、大腸)分析、バイオマーカー種類別(ゲノムバイオマーカー、タンパク質バイオマーカー)分析、用途別(診断、予後)分析、がん・腫瘍プロファイリングの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Cancer/tumor profiling market is projected to grow at a CAGR of 10.5% during the forecast period (2019–2024).”Cancer/tumor profiling market is projected to reach USD 12.4 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 10.5%. The increasing incidence of cancer across the globe and the rising use of biomarkers in tumor profiling are the primary growth drivers for this market. Additionally, the increase in cancer research & funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market.

The increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, the high capital investment required for biomarker discovery and the technical issues with sample collection and storage are the key factors restraining the market growth.

“The next-generation sequencing (NGS) segment is expected to grow at the highest rate during the forecast period.”
Based on technology, cancer/tumor profiling market has been segmented into immunoassays, in-situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The next-generation sequencing (NGS) segment is projected to witness the highest growth in cancer/tumor profiling market during the forecast period. The benefits of effectively exploring genetic alterations in a wide range of cancers and the identification of a number of differentially expressed genes & genetic/epigenetic variants as potential targets aid in the development of new biomarkers for early diagnosis of the disease. These factors are supporting the adoption of NGS technology in cancer/tumor profiling market.

“The lung cancer segment is expected to grow at the highest CAGR during the forecast period.”
Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing incidence of lung cancer worldwide and the growing need for early diagnosis are supporting the growth of this segment.

“The protein biomarkers segment is expected to grow at the highest CAGR during the forecast period.”
Based on biomarker type, cancer/tumor profiling market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. The protein biomarkers segment is estimated to grow at the highest CAGR during the forecast period majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase an enormous potential for directing personalized cancer therapy and treatment monitoring.

“The clinical applications segment is expected to grow at the highest rate during the forecast period.”
Based on applications, cancer/tumor profiling market is segmented into research and clinical applications. The research applications segment is further sub-segmented into biomarker discovery and personalized medicine. On the other hand, the clinical applications segment is sub-segmented into diagnostics, prognostics, screening, and monitoring & treatment.

The clinical applications segment is expected to grow at the highest CAGR during the forecast period. With the increasing incidence rate of cancers across the globe and the rising availability of molecular profiling, and functional assessment of signaling pathways of advanced solid tumors, the use of tumor profiling techniques is gaining momentum for clinical practice.

“APAC is projected to witness the highest growth during the forecast period.”
Although North America is expected to account for the largest share of global cancer/tumor profiling market in 2018, APAC is expected to witness the highest CAGR during the forecast period. This is primarily due to the high incidence of cancer, growing proteomics & genomics research, rising research funding, increasing investments by pharmaceutical & biotechnology companies, and growing awareness about personalized therapeutics.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation: C-level–35%, Director-level–25%, and Others–40%
• By Region: North America–45%, Europe–30%, Asia Pacific–20%, Rest of the World-5%

The prominent players in cancer/tumor profiling market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).
Research Coverage:
The report analyzes the market for various cancer/tumor profiling technologies and their adoption pattern. It aims at estimating the market size and future growth potential of cancer/tumor profiling market and the different segments such as by technology, cancer type, biomarker type, and application. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a more significant share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in cancer/tumor profiling market.
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in cancer/tumor profiling market.
• Market Development: Comprehensive information on lucrative emerging regions.
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in global cancer/tumor profiling market.
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading players in cancer/tumor profiling market.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 19
1.3.1.1 Markets covered 20
1.3.1.2 Years considered for the study 20
1.4 CURRENCY 21
1.5 STAKEHOLDERS 21
1.6 LIMITATIONS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH APPROACH 22
2.1.1 SECONDARY RESEARCH 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY RESEARCH 24
2.1.2.1 Key data from primary sources 24
2.1.2.2 Breakdown of primaries 25
2.1.2.3 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 26
2.3 DATA TRIANGULATION APPROACH 28
2.4 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 35
4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW 35
4.2 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 36
4.3 REGIONAL MIX: CANCER/TUMOR PROFILING MARKET (2019–2024) 37
4.4 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. DEVELOPING MARKETS (2019 VS. 2024) 38
5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 MARKET DRIVERS 40
5.2.1.1 Increasing incidence of cancer 40
5.2.1.2 Increasing use of biomarkers in cancer profiling 40
5.2.1.3 Increasing cancer research and funding 41
5.2.1.4 Technological advancements 42
5.2.2 MARKET RESTRAINTS 43
5.2.2.1 High capital investment 43
5.2.2.2 Technical issues with sample collection and storage 43
5.2.3 MARKET OPPORTUNITIES 44
5.2.3.1 Increasing demand for personalized medicine 44
5.2.3.2 Growing need for point-of-care diagnostics 45
5.2.4 MARKET CHALLENGES 46
5.2.4.1 Low biomarker discovery-to-approval ratio 46
5.2.4.2 Poor regulatory and reimbursement scenario 46
6 INDUSTRY INSIGHTS 48
6.1 INTRODUCTION 48
6.2 INDUSTRY TRENDS 48
6.2.1 INTEGRATION OF OMICS DATA 49
6.2.2 ADVANCES IN LIQUID BIOPSY 49
6.2.3 ORGANOIDS FOR PERSONALIZED MEDICINE 50
7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY 51
7.1 INTRODUCTION 52
7.2 IMMUNOASSAYS 53
7.2.1 IMMUNOASSAY TESTS IDENTIFY AND ASSESS THE PROGRESSION OF DISEASE, THEREBY PROVIDING INFORMATION VITAL FOR BETTER THERAPEUTIC CHOICES 53
7.3 NEXT-GENERATION SEQUENCING 55
7.3.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES ENABLE ONE ASSAY TO PROVIDE A COMPLETE TUMOR MOLECULAR PROFILE 55
7.4 POLYMERASE CHAIN REACTION 56
7.4.1 REAL-TIME PCR HELPS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS, AIDING BIOMARKER IDENTIFICATION 56
7.5 IN SITU HYBRIDIZATION 58
7.5.1 FISH IS THE GOLD STANDARD FOR EVALUATING SOME KEY BIOMARKERS AND PLAYS A CRITICAL ROLE IN GUIDING TARGETED THERAPIES 58
7.6 MICROARRAYS 60
7.6.1 MICROARRAYS ARE WIDELY ADOPTED IN DIAGNOSTICS AS THEY AID IN PREDICTING THE RECURRENCE OF CANCER AFTER TREATMENT 60
7.7 MASS SPECTROMETRY 62
7.7.1 TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNOLOGY FOR SENSITIVE, RELIABLE, AND RAPID DIAGNOSIS 62
7.8 OTHER TECHNOLOGIES 63

8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE 65
8.1 INTRODUCTION 66
8.2 BREAST CANCER 67
8.2.1 BREAST CANCER IS THE MOST COMMON CANCER FOUND AMONG WOMEN 67
8.3 LUNG CANCER 69
8.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS HAS IS A KEY TOOL FOR THE CLINICAL MANAGEMENT OF NSCLC PATIENTS 69
8.4 COLORECTAL CANCER 71
8.4.1 IHC, PCR, MICROARRAYS, AND IMAGING TECHNOLOGIES ARE MAJOR TECHNOLOGIES USED IN COLORECTAL DIAGNOSTICS 71
8.5 PROSTATE CANCER 72
8.5.1 PROSTATE-SPECIFIC ANTIGEN IS A WIDELY USED FDA-APPROVED BIOMARKER FOR PROSTATE CANCER SCREENING 72
8.6 MELANOMA 74
8.6.1 RT-QPCR IS GENERALLY UTILIZED TO CONDUCT MOLECULAR PROFILING AND ANALYZE BIOMARKERS IN MELANOMAS 74
8.7 OTHER CANCERS 75
9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE 77
9.1 INTRODUCTION 78
9.2 GENETIC BIOMARKERS 79
9.2.1 GENETIC BIOMARKERS ARE FREQUENTLY USED IN CLINICAL PRACTICE FOR DIAGNOSIS AND PROGNOSIS 79
9.3 PROTEIN BIOMARKERS 80
9.3.1 PROTEOMIC METHODS SHOWCASE SIGNIFICANT PROMISE FOR THE DISCOVERY OF NOVEL BIOMARKERS 80
9.4 OTHER BIOMARKERS 82
10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION 84
10.1 INTRODUCTION 85
10.2 RESEARCH APPLICATIONS 86
10.2.1 BIOMARKER DISCOVERY 87
10.2.1.1 Biomarkers are being exploited for the development of personalized or precision medicine 87
10.2.2 PERSONALIZED MEDICINE 88
10.2.2.1 The field of personalized medicine is witnessing rapid growth in the area of oncology 88
10.3 CLINICAL APPLICATIONS 90
10.3.1 DIAGNOSTICS 90
10.3.1.1 Tumor profiling is rapidly gaining momentum in the area of diagnostics 90
10.3.2 PROGNOSTICS 92
10.3.2.1 Advancements in molecular biology are aiding the uptake of tumor profiling in this segment 92

10.3.3 MONITORING & TREATMENT 93
10.3.3.1 Multiplatform profiling analyses are gaining recognition for monitoring and treatment among cancer patients 93
10.3.4 SCREENING 94
10.3.4.1 Screening tests help in deciding if diagnostic tests are required by the patient 94
11 CANCER/TUMOR PROFILING MARKET, BY REGION 95
11.1 INTRODUCTION 96
11.2 NORTH AMERICA 97
11.2.1 US 101
11.2.1.1 US dominates the North American cancer/tumor profiling market 101
11.2.2 CANADA 105
11.2.2.1 Growing public-private partnerships to promote proteomics research are expected to drive the market in Canada 105
11.3 EUROPE 108
11.3.1 GERMANY 113
11.3.1.1 Advancements proteomics and genomics research are expected to drive market growth 113
11.3.2 UK 116
11.3.2.1 Growth in the life science industry and the increase in academia-industry partnerships will be the key factors driving the market 116
11.3.3 FRANCE 119
11.3.3.1 Growth in this market is primarily driven by increasing investments in life science R&D for infrastructural development 119
11.3.4 ITALY 122
11.3.4.1 Increasing investment in cancer and translational research is expected to propel market growth during the forecast period 122
11.3.5 SPAIN 125
11.3.5.1 Rising incidence of cancer and increasing focus on cancer biomarkers by various medical societies to support market growth in Spain 125
11.3.6 REST OF EUROPE 128
11.4 ASIA PACIFIC 131
11.4.1 JAPAN 136
11.4.1.1 Large number of research initiatives towards the development of precision medicine supporting market growth in Japan 136
11.4.2 CHINA 139
11.4.2.1 China has the fastest-growing research sector in the APAC region 139
11.4.3 INDIA 142
11.4.3.1 Increasing pharma R&D and government funding in the biotechnology industry are the major factors driving market growth in India 142
11.4.4 REST OF ASIA PACIFIC 145

11.5 LATIN AMERICA 148
11.5.1 GROWING PROTEOMICS RESEARCH IN THE FIELD OF CANCER ALONG WITH THE RISING USE OF ADVANCED TECHNIQUES TO DRIVE MARKET GROWTH 148
11.6 MIDDLE EAST & AFRICA 151
11.6.1 GROWING GENOMICS AND PROTEOMICS RESEARCH AND INCREASING RESEARCH COLLABORATIONS ARE EXPECTED TO SUPPORT MARKET GROWTH 151
12 COMPETITIVE LANDSCAPE 155
12.1 OVERVIEW 155
12.2 COMPETITIVE LEADERSHIP MAPPING 156
12.2.1 VISIONARY LEADERS 156
12.2.2 INNOVATORS 156
12.2.3 DYNAMIC DIFFERENTIATORS 156
12.2.4 EMERGING COMPANIES 157
12.3 COMPETITIVE SITUATION AND TRENDS 158
12.3.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS 158
12.3.2 EXPANSIONS 159
12.3.3 ACQUISITIONS 160
12.3.4 OTHER STRATEGIES 161
13 COMPANY PROFILES 162
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1 ILLUMINA, INC. 162
13.2 QIAGEN N.V. 168
13.3 NEOGENOMIC LABORATORIES, INC. 175
13.4 SYSMEX CORPORATION 181
13.5 HTG MOLECULAR DIAGNOSTICS, INC. 186
13.6 HELOMICS CORPORATION 191
13.7 GENOMIC HEALTH, INC. 195
13.8 CARIS LIFE SCIENCES 198
13.9 NANOSTRING TECHNOLOGIES, INC. 200
13.10 RIBOMED BIOTECHNOLOGIES, INC. 204
13.11 GUARDANT HEALTH, INC. 206
13.12 FOUNDATION MEDICINE 209
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

14 APPENDIX 213
14.1 INSIGHTS OF INDUSTRY EXPERTS 213
14.2 MARKET SIZING & VALIDATION APPROACH 214
14.3 DISCUSSION GUIDE 216
14.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 220
14.5 AVAILABLE CUSTOMIZATIONS 222
14.6 RELATED REPORTS 222
14.7 AUTHOR DETAILS 223

LIST OF TABLES

TABLE 1 MARKET DRIVERS: IMPACT ANALYSIS 42
TABLE 2 MARKET RESTRAINTS: IMPACT ANALYSIS 44
TABLE 3 MARKET OPPORTUNITIES: IMPACT ANALYSIS 45
TABLE 4 MARKET CHALLENGES: IMPACT ANALYSIS 47
TABLE 5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 53
TABLE 6 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY,
2017–2024 (USD MILLION) 54
TABLE 7 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2017–2024 (USD MILLION) 56
TABLE 8 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 9 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017–2024 (USD MILLION) 59
TABLE 10 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY,
2017–2024 (USD MILLION) 61
TABLE 11 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2017–2024 (USD MILLION) 63
TABLE 12 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 64
TABLE 13 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 66
TABLE 14 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY,
2017–2024 (USD MILLION) 68
TABLE 15 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY,
2017–2024 (USD MILLION) 70
TABLE 16 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017–2024 (USD MILLION) 72
TABLE 17 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY,
2017–2024 (USD MILLION) 74
TABLE 19 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY,
2017–2024 (USD MILLION) 76
TABLE 20 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 79
TABLE 21 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION) 80
TABLE 22 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION) 81
TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION) 83
TABLE 24 CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 85
TABLE 25 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 86
TABLE 26 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2017–2024 (USD MILLION) 87
TABLE 27 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2017–2024 (USD MILLION) 89
TABLE 28 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 90
TABLE 29 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY,
2017–2024 (USD MILLION) 91
TABLE 30 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY,
2017–2024 (USD MILLION) 92
TABLE 31 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT,
BY COUNTRY, 2017–2024 (USD MILLION) 93
TABLE 32 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY,
2017–2024 (USD MILLION) 94
TABLE 33 CANCER/TUMOR PROFILING MARKET, BY REGION, 2017–2024 (USD MILLION) 97
TABLE 34 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 99
TABLE 35 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 99
TABLE 36 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 100
TABLE 37 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION) 100
TABLE 38 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 39 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 40 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 102
TABLE 41 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 103
TABLE 42 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 103
TABLE 43 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 104
TABLE 44 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 104
TABLE 45 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 106
TABLE 46 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 106
TABLE 47 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 107
TABLE 48 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 107
TABLE 49 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 107
TABLE 50 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 110
TABLE 51 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 110
TABLE 52 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 111
TABLE 53 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 111
TABLE 54 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 112
TABLE 55 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 112
TABLE 56 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 114
TABLE 57 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 114
TABLE 58 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 115
TABLE 59 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 115
TABLE 60 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 116
TABLE 61 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 117
TABLE 62 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 117
TABLE 63 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 118
TABLE 64 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 118
TABLE 65 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 119
TABLE 66 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 120
TABLE 67 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 120
TABLE 68 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 121
TABLE 69 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 121
TABLE 70 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 122
TABLE 71 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 123
TABLE 72 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 123
TABLE 73 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 124
TABLE 74 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 124
TABLE 75 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 125
TABLE 76 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 126
TABLE 77 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 126
TABLE 78 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 127
TABLE 79 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 127
TABLE 80 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 128
TABLE 81 ROE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 129
TABLE 82 ROE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 129
TABLE 83 ROE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 130
TABLE 84 ROE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 130
TABLE 85 ROE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 130
TABLE 86 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 133
TABLE 87 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 133
TABLE 88 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 134
TABLE 89 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 134
TABLE 90 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 91 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 92 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 137
TABLE 93 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 137
TABLE 94 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 138
TABLE 95 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 138
TABLE 96 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 138
TABLE 97 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 140
TABLE 98 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 140
TABLE 99 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 141
TABLE 100 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 141
TABLE 101 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 141
TABLE 102 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 143
TABLE 103 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 143
TABLE 104 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 144
TABLE 105 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 144
TABLE 106 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 144
TABLE 107 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 146
TABLE 108 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 146
TABLE 109 ROAPAC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION) 147
TABLE 110 ROAPAC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 147
TABLE 111 ROAPAC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 147
TABLE 112 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 149
TABLE 113 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 149
TABLE 114 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION) 150
TABLE 115 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 116 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 117 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 152
TABLE 118 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 152
TABLE 119 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION) 153
TABLE 120 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 153
TABLE 121 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 154


LIST OF FIGURES

FIGURE 1 CANCER/TUMOR PROFILING MARKET 20
FIGURE 2 RESEARCH DESIGN 22
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS,
AND REGION 25
FIGURE 4 BOTTOM-UP APPROACH 27
FIGURE 5 TOP-DOWN APPROACH 27
FIGURE 6 DATA TRIANGULATION METHODOLOGY 28
FIGURE 7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2019 VS. 2024 (USD MILLION) 30
FIGURE 8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2019 VS. 2024 (USD MILLION) 31
FIGURE 9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2019 VS. 2024 (USD MILLION) 32
FIGURE 10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2019 VS. 2024 (USD MILLION) 32
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET 33
FIGURE 12 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 35
FIGURE 13 CHINA TO REGISTER THE HIGHEST GROWTH IN THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD 36
FIGURE 14 APAC TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST
PERIOD (2019–2024) 37
FIGURE 15 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN
2019 & 2024 38
FIGURE 16 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
FIGURE 17 GLOBAL CANCER INCIDENCE, 2008–2030 40
FIGURE 18 LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008–2016 44
FIGURE 19 INCREASING USE OF INTEGRATED OMICS DATA AND GROWING FOCUS ON LIQUID BIOPSY TESTS ARE KEY MARKET TRENDS 48
FIGURE 20 IMMUNOASSAYS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD 52
FIGURE 21 BREAST CANCER SEGMENT TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD 66
FIGURE 22 GLOBAL LUNG CANCER INCIDENCE, 2012-2030 69
FIGURE 23 COLORECTAL CANCER INCIDENCE RATE, KEY COUNTRIES (2018) 71
FIGURE 24 GENETIC BIOMARKERS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD 78
FIGURE 25 RESEARCH APPLICATIONS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD 85
FIGURE 26 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2018) 96
FIGURE 27 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT 98
FIGURE 28 EUROPE: CANCER/TUMOR PROFILING MARKET SNAPSHOT 109
FIGURE 29 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT 132
FIGURE 30 ILLUMINA, INC.: COMPANY SNAPSHOT (2018) 162
FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT (2018) 168
FIGURE 32 NEOGENOMIC LABORATORIES, INC.: COMPANY SNAPSHOT (2018) 175
FIGURE 33 SYSMEX CORPORATION: COMPANY SNAPSHOT (2018) 181
FIGURE 34 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2018) 186
FIGURE 35 GENOMIC HEALTH, INC.: COMPANY SNAPSHOT (2018) 195
FIGURE 36 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2018) 200
FIGURE 37 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2018) 206
FIGURE 38 FOUNDATION MEDICINE: COMPANY SNAPSHOT (2018) 209


★調査レポート[がん・腫瘍プロファイリングの世界市場予測(~2024年):イムノアッセイ、NGS、PCR、in situハイブリダイゼーション] ( Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024 / MD 4803) 販売に関する免責事項
[がん・腫瘍プロファイリングの世界市場予測(~2024年):イムノアッセイ、NGS、PCR、in situハイブリダイゼーション] ( Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024 / MD 4803) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆